Qiagen vs Spyre Therapeutics

Qiagen (QGEN), health care, and Spyre Therapeutics (SYRE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Qiagen is worth $10.3B on the stock market and Spyre Therapeutics $8.9B: Qiagen is valued at 15% more. Over the past year Qiagen's share price has moved +12.3% and Spyre Therapeutics's +312%.

Key facts

Qiagen market value
$10.3B
Spyre Therapeutics market value
$8.9B
Qiagen P/E
26.9
Qiagen revenue
$2.1BFY to 2025-12-31
Spyre Therapeutics revenue
$0FY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Qiagen vs Spyre Therapeutics: every measure side by side
Measure Qiagen Spyre Therapeutics
SectorHealth CareHealth Care
Country Netherlands United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.3Bhigher$8.9Blower
Revenue$2.1Bhigher$0lower
Earnings$424.9Mhigher-$155.2Mlower
Employees5,400higher130lower
Total assets$6.3Bhigher$777.8Mlower
Valuation
P/E26.9—
P/S4.9—
P/B—9.3
Dividend yield—0.00%
Profitability
Operating margin22.3%—
Balance sheet
Net assets$3.8Bhigher$715.2Mlower
Total liabilities$2.5Bhigher$62.5Mlower
Total debt$1.7B—
Cash on hand$839Mhigher$85.7Mlower
Price change
Today-0.12%higher-5.60%lower
1 year+12.3%lower+312%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Qiagen only (0)

None of the tracked investors.

Spyre Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. · Who owns SYRE

Further comparisons

Learn

Questions and answers

Which is bigger, Qiagen or Spyre Therapeutics?

By market value, Qiagen is the larger: $10.3B against $8.9B for Spyre Therapeutics. By revenue in its latest fiscal year, Qiagen is the larger: $2.1B against $0 for Spyre Therapeutics.

Which superinvestors own both Qiagen and Spyre Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Qiagen and 1 holds Spyre Therapeutics.

Cite this page

Funkfolio, “Qiagen vs Spyre Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/qgen-vs-syre

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.